Default company panoramic image
Cbb9e599 5d4a 427f 94f1 1d618ba28712

Spordiff Therapeutics

Unique small molecule inhibiting C diff germination, preventing most common hospital acquired infection, a $4B annual problem

  • Stage Product In Development
  • Industry Biotechnology
  • Location Belmont, MA, USA
  • Currency USD
  • Employees 0
  • Website

Company Summary

Spordiff Therapeutics is developing a small molecule to prevent Clostridium difficile (C. diff) antibiotic-associated colitis (AAC), which accounts for 50% of all hospital-acquired infections and results in healthcare costs of around $4 billion annually. The Spordiff approach will prevent onset of AAC by inhibiting germination of C. diff spores, resulting in a new standard of care. Current therapies are used only after illness appears.


  • Default avatar
    Frederick (Rick) Jones

    Extensive global experience as senior executive in biotech and pharma, including significant deal-making and capital formation. Previous positions at Anchor, Devgen, BioRexis, Wyeth.


  • Default avatar
    Bill Whelan, Mintz
    Default avatar
    Gregg Beloff, Danforth Associates